IRTC Stock — iRhythm Holdings, Inc.

Up next

Next earnings call

Nov 9, 2026 Est · unconfirmed · in 8 wks

Latest filing: 10-Q

filed Aug 6, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$825.34M

Trailing 12 months

Net income (TTM)

−$13.95M

Trailing 12 months

Revenue growth YoY

+20.1%

Year over year

Operating margin

-3.0%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

1.1%

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

—

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+2.8%

Year over year · more shares

Price change (1Y)

-38.4%

Trailing year

Short interest

8.5%

Latest settlement · 5.6 days to cover

View all 115 metrics

AI Brief

Q2 FY26 earnings call · Aug 6, 2026

Q2 FY26

TL;DR. iRhythm reported Q2 2026 revenue of $224.2M (+20.1% YoY) with adjusted EBITDA margin of 19.3% (+1,090 bps) and raised full-year 2026 revenue guidance to $880M-$890M and adjusted EBITDA margin guidance to 13.0%-14.0%, while announcing a $287.5M acquisition of Vital Connect to expand into MCT and multi-vitals monitoring.

Bullish

+ Raised full-year 2026 revenue guidance to $880M-$890M and adjusted EBITDA margin guidance to 13.0%-14.0%.
+ Q2 revenue grew 20.1% YoY to $224.2M, the seventh consecutive quarter of >20% growth.
+ Adjusted EBITDA margin expanded ~1,090 bps YoY to 19.3% and gross margin improved 160 bps to 72.8%.
+ Record free cash flow of $37.5M and $591.3M in cash and marketable securities.
+ FDA clearance of third-generation algorithm expected to deliver ~$100M cumulative cost savings over five years.
+ Announced $287.5M acquisition of Vital Connect to expand into MCT and multi-vitals, with positive revenue contribution beginning 2027 while maintaining 15% adjusted EBITDA margin target.

Bearish

− Agreed to $50M litigation settlement payment to Baxter/Welch Allyn/Bardy Diagnostics on July 31, 2026.
− Vital Connect acquisition will deploy approximately $237.5M in cash, plus up to $30M in interim working capital financing, materially reducing the cash balance.
− Company remains subject to an FDA warning letter with remediation completion pending agency review.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Excellent Quant / Vol Very High

Market backdrop VIX 15.8 · calm Equity put/call 0.58

Technical

price trend

Strong Sell

50 / 200-day cross No cross

Price vs 200-day avg −17%

below

Price vs 50-day avg −7%

below

RSI (14) 38

neutral

MACD trend Negative

52-week position 11%

near low

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Weak

1-month return −10%

trailing

6-month return −4%

trailing

YTD return −37%

this year

Relative strength −22%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $120 › 200d $134 — 200d above 50d

Institutional flow Distributing

-0% holders QoQ · +45 funds added

Insider flow Distributing

Net -$7.7M over 90 days · 100% sells

Short interest Falling

8.46% of float · ▼ -0.4% MoM · 5.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

305 holders — mid 3-yr range

Squeeze score 63

elevated · 0–100

Fundamentals

Excellent

Revenue growth +26%

Y/Y

Gross margin 71%

expanding

EPS growth +62%

Y/Y

Free cash flow $34.5M

Balance sheet $106.2M

net cash

Quant / Vol

risk profile

Very High

Volatility 44%

annualized · 1-yr

Max drawdown −46%

past year

ATR 5.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Beat or met 3 of last 3

Latest guidance · from the 8-K filed Aug 6, 2026

full year 2026

Revenue Initiated $880M – $890M

prior FY $747.14M midpoint +18.5% Y/Y

Adjusted EBITDA margin Non-GAAP Initiated 13% – 14%

2027

Adjusted EBITDA margin Non-GAAP 15%

Prior guidance period ended · from the 8-K filed Aug 1, 2024

Revenue · full year 2024 $580M – $590M

Gross margin · full year 2024 68.5% – 69%

Guided vs delivered · last 3 settled

Revenue full year 2024

guided $580M – $590M

guided $580M – $590M $591.84M Beat +1.2%

Revenue full year 2021

guided $317M – $319M

guided $317M – $319M $322.83M Beat +1.5%

Revenue fourth quarter of 2021

guided $76M – $78M

guided $76M – $78M $81.8M Beat +6.2%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Sell

4 · 3 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−17% Bearish

Price vs 50-day avg

−7% Bearish

RSI (14)

38 Neutral

MACD trend

Negative Bearish

52-week position

11% Bearish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bearish · 2 of 6

Trend (MA cross) No cross

50d $120 › 200d $134 — 200d above 50d

Institutional flow Distributing

-0% holders QoQ · +45 funds added

Insider flow Distributing

Net -$7.7M over 90 days · 100% sells

Short interest Falling

8.46% of float · ▼ -0.4% MoM · 5.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

305 holders — mid 3-yr range

Price context

position in its 52-week range

Range low $102 Now $111 · 11% Range high $189

vs 200-day avg -17% vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Medical Devices — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
IRTC iRhythm Holdings, Inc. this stock	$3.67B	-37.2%	+26.2%	—	8.5%
ABT Abbott Laboratories	$177.58B	-18.6%	+5.7%	28.6	1.3%
MDT Medtronic plc	$116.35B	-5.3%	+8.4%	22.4	0.9%
SYK Stryker Corp	$105.70B	-21.6%	+11.2%	28.6	2.0%
BSX Boston Scientific Corp	$62.29B	-54.9%	+12.5%	17.4	3.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

305

% held: 108.4%
Net QoQ: +43.0K sh
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

306

View

Short & Settlement

Short Interest Falling

Shares short

2.8M

Days to cover: 5.6d
Change: -12.4K sh

View

Short Volume

Short vol %

64%

As of: Sep 11, 2026

Short Total

View

Fails to Deliver

FTD shares

22

Value: $2.5K
As of: Jul 16, 2026

View

Off-Exchange

Off-exchange %

45.8%

Week of: Aug 3, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$7.7M

Buyers / Sellers: 0 / 9

Buyers Sellers

View

Congressional Trades Sell

Member

Donna Shalala

Amount: $1.0K–$15.0K
Traded: Jun 24, 2019

View

Financials

Revenue (FY)

$747.1M

Net income (FY): $-44.6M
EPS diluted: $-1.39

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 9, 2026
This year: 17

View

Proposed Sales

Value

$626.4K

Shares: 5.3K
Filed: May 11, 2026

View

Earnings & Events

Earnings Calls

Last call

Sep 9, 2026

View

Investor Relations

	5D	20D	120D	MTD	YTD
IRTC	-9.7%	-9.5%	-4.2%	-6.3%	-37.2%
SPY	-1.2%	-1.8%	+17.8%	-0.4%	+12.1%
vs SPY	-8.6%	-7.8%	-22.0%	-6.0%	-49.3%

IRTC · iRhythm Holdings, Inc.

Price & Indicators

Up next

Metrics snapshot

AI Brief

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance